Vivani’s implant group lost nearly as much weight as the Wegovy group, and none of its 10 participants had treatment-related side effects. The 4-week study was small, but its results support Vivani’s planned next trial.
That comparison suggests the implant may deliver similar early weight loss with fewer reported side effects. But only 10 people received it, and the study lasted 4 weeks. Vivani plans another trial in 2027, so the implant still needs more testing.
Novo Nordisk is assessing Vivani’s implant under a non-exclusive agreement. The report gives no change to Novo’s sales or plans, so it does not change Novo’s outlook.
Follow Vivani Medical Inc. (VANI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for VANI